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Human immunodeficiency virus (HIV) establishes a latent infection in cells to 
ensure a persistent infection throughout an infected individual’s life. HIV can establish 
this latent infection in a variety of cells. Highly Active Anti-Retroviral Treatment 
(HAART) is a selection of drugs used to inhibit the production of new HIV and new 
infections and can effectively diminish virus population in blood. However, due to the 
pathological mechanism of the virus, it is not possible yet to completely eradicate virus as 
it remains immunologically invisible in latent cellular reservoirs. The cellular reservoirs 
where HIV evades the immune system are not known completely. Current research 
efforts are focused on identifying the cellular populations where HIV remains latent and 
determine how those latent reservoirs are established. By identifying latent cellular 
reservoirs where HIV resides strategies can be developed to target and kill infected cells 
or prevent emergence of virus. We hypothesized that primary, skin, human mast cells 
may represent a previously unknown latent reservoir for HIV. Because mast cells can be 
activated through IgE-and non-IgE-dependent stimulation, we further hypothesized 
activated mast cells may be more vulnerable to infection. Our experimentations suggest 
that skin-derived mast cells are not susceptible to HIV infection and are not an inducible 
reservoir for HIV. 
One strategy for inhibiting viral replication has been with fullerenes. Fullerenes 
are carbon spheres that can be functionalized for use in various biological systems. 
Fullerenes functionalized with large dendrimeric moieties have been shown previously to 
 
 
inhibit viral replication in vitro, but the majority of investigations that have explored 
fullerenes as an inhibitor of HIV were assessed computationally. Based on these previous 
studies we hypothesized that certain functionalized fullerenes will suppress HIV 
infectivity and/or replication. We hypothesized that these fullerenes may interact with 
HIV protease and performed molecular modeled docking studies to investigate this idea. 
We also performed in vitro dose response assays on certain fullerene derivatives and our 
findings suggest they were effective at suppressing the virus. 
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CHAPTER I 
INTRODUCTION 
 
Since its discovery in 1983, HIV has infected over 70 million people and killed 35 
million people [1]. The virus targets the immune system of infected individuals and if left 
untreated leads to a condition known as Acquired Immune Deficiency Syndrome (AIDS). 
An individual is classified as having AIDS when their CD4+ cell count drops below 200 
cells per mm
3
 of blood [2]. At this point, opportunistic infections have much larger 
effects, including death in some cases. Many methods have been discovered and 
employed to help infected people survive the infection, but there still is no cure or 
effective vaccine to stop the virus. Of those methods available to effectively decrease the 
probability of progression to AIDS for infected individuals, Highly Active Antiretroviral 
Therapy (HAART) has been used with great success and is the most often used option for 
infected individuals. HAART works by inhibiting viral functions and/or by bolstering the 
host’s immune system [3]. 
I.1 Human Immunodeficiency Virus as a Medical Problem 
 HIV primarily infects CD4+ cells in vivo and a select population of all cells 
infected becomes long-lived latent reservoirs from which new virions can be produced 
long after levels of viral markers are no longer detectable in blood samples [4,5]. Latent 
reservoirs are effectively invisible to the immune system and nearly all treatments [6]. 
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Latency is maintained through a variety of mechanisms and those mechanisms are often 
reinforced through HAART medications [7]. After the suspension of HAART 
medication, patients experience explosions of virus production [8]. Consequently, CD4+ 
cell counts drop and AIDS can be developed. 
Current research efforts have focused on identifying the latent reservoirs in vivo 
and one possible latent reservoir may be established in the mast cell. Several studies have 
examined the possibility of mast cells from various tissue sites for the susceptibility to 
HIV with varied results [9-20]. Their examination is due to the fact that they are 
ubiquitously expressed and are often one of the first immune cells to come into contact 
with the virus. As demonstrated below, mast cells derived from human, excised skin are 
assessed for their susceptibility to HIV both with and without degranulating activation. 
The HAART therapy is often comprised of several components that target many 
viral processes and interrupt them. One enzyme process that is often targeted for 
interruption is the HIV protease. Disruption of the proteases activity disables the newly-
budded, immature virus from effectively infecting new cells by stopping the cleaving 
process necessary for matrix proteins to assemble [21,22]. Because HIV protease is a 
desirable target for drug therapies, protease inhibitors were developed as a class of anti-
retroviral drugs that are effective at limiting the virus’ potential to infect new cells 
[23,24]. Fullerenes and their derivatives were identified as potential analogs to these 
protease inhibitors by Friedman et al because of the hydrophobicity of both the fullerene 
cage and the active site of HIV protease [25].  Following that initial realization and 
computational calculation, researchers have identified several fullerene derivatives that 
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likely or experimentally have inhibitory effects on the HIV protease or suppressive 
effects on the virus’ proliferation [26-28]. This thesis included both preliminary 
computational evaluations of a panel of previously untested fullerene derivatives and 
their potential interaction to HIV protease as well as a dose response assay assessing their 
effectiveness as a viral suppressor.
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CHAPTER II  
REVIEW OF THE LITERATURE 
 
II.1 HIV Infection 
 HIV is well known for infecting human helper T-cells. There are several different 
variations of T-cells, some being classified as being a part of the adaptive immune system 
and others being classified as being part of the innate immune system [29,30].  Helper T-
cells are susceptible to infection because HIV primarily targets the surface receptor CD4 
[31]. When HIV infects a cell, it follows a multi-step process. The first step is the 
attachment of CD4 to viral gp120. This binding event causes conformational changes in 
gp120 and CD4 allowing for a second binding event with between gp120 and either 
CCR5 or CXCR4, depending on the tropism of the virus [32-34]. After this binding 
event, viral gp41 is able to pierce the cell’s membrane. Then, conformational changes in 
gp41 allow the membrane of the virus to fuse with the membrane of the cell and the viral 
capsid is injected into the cell. The viral capsid dissociates and reverse transcriptase binds 
to and transports the viral RNA toward the nucleus [21,35]. On the way, viral RNA is 
reverse transcribed into DNA by viral reverse transcriptase.  The viral DNA is then 
transported into the nuclease by viral integrase [36]. There, viral integrase inserts the 
viral DNA into the host cell’s DNA. From here, the virus can continue to spread the 
infection by entering into an active replication phase or can enter into a latency phase and 
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is termed the “point of no return” because of the irreversibility of the integration process 
[37]. 
In the former, the virus uses nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and other host transcription factors and later viral transcription 
factors to transcribe various viral transcripts [38]. These transcripts are then translated 
into the viral proteins necessary for new virion production. As new viral material is 
produced it gathers at the cell membrane and is packaged into budding, immature virions 
[21]. After budding away from the cell, these immature virions require the proteolytic 
activity of HIV protease to allow for the construction of the viral capsid and therefore 
mature. Without maturation, the virions have high failure rates trying to infect new cells 
[22]. 
II.2 HIV Latency 
The other phase that the cell may enter is latency. The latently infected cell 
harbors viral DNA and is effectively protected from immunogenicity. Latently infected 
cells can remain dormant indefinitely and may be activated at any time allowing the virus 
to begin producing new virions and infecting new cells [8]. Therefore, continued 
administration of HAART drugs is necessary to disallow progression to AIDS. Several 
latent reservoirs have been identified in memory T-cells, tissue macrophages, as well as 
possibly hematopoietic stem cells, though this is disputed [5,9,39-43]. Mechanisms that 
cause latency vary from cell to cell [7]. Also, there may be more than one mechanism that 
is working in the cell that maintains the latency. Several mechanisms may inhibit viral 
gene expression, including non-functional mutations in the viral DNA, transcriptional 
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interference, epigenetic silencing, changes in chromatin structure, negative transcription 
factor interference, absence of positive transcription factors, and problems with RNA 
transport and translation [44-59]. An important factor in the integration process of 
infection is that the virus preferentially inserts its DNA into genes that are actively being 
expressed [60]. This means that for cells that are latently infected, they can be activated 
to produce native proteins while at the same time upregulating the genes necessary for 
viral replication [43]. While not all CD4+ cells are prone to activation, many are and their 
activation may have an effect on the pathology of the virus. 
II.3 Medical Response to HIV Infection 
HAART is a treatment regimen composed of drugs that either boost the infected 
individual’s immune system or target viral processes to stop them from progressing. Viral 
inhibitors used range in specific viral process targeting, but generally work in one of six 
ways. CCR5 antagonists, also known as entry inhibitors, bind to the active site of the 
CCR5 surface receptor on host cells [61]. By binding to CCR5, these drugs disallow the 
secondary binding event of HIV to the cell, thereby stopping the virus from entering the 
cell. A second drug class used in the inhibition of HIV processes is fusion inhibitors. 
Fusion inhibitors bind to envelope proteins on the virus and stop the conformational 
changes necessary to actually allow fusion of the viral and host cell membranes [62,63]. 
There are two types of reverse transcriptase inhibitors used in HIV medication. The first 
are termed non-nucleoside reverse transcriptase inhibitors and they work by directly 
binding to the reverse transcriptase enzyme and stop it from working [64-66]. The second 
type is nucleoside reverse transcriptase inhibitors. These were the first drugs available to 
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treat HIV infected individuals and work by terminating newly reverse transcribed DNA 
[67]. It does this by mimicking naturally available deoxyribonucleotides that are used to 
synthesize new DNA. These mimics lack a necessary 3’-hydroxyl group and cannot bind 
additional nucleotides effectively terminating the reverse transcription. This process is 
called chain termination and can cause adverse side effects. Integrase inhibitors are 
another class of drugs used in anti-retroviral therapy. As their name suggests, they stop 
integrase from functioning properly and stop the virus from infecting the cell [68,69]. 
The final type of drug used in HAART therapies are protease inhibitors. HIV protease 
(HIVP) is used by the virus to mature newly formed virions [22,70]. After budding away 
from the host cell, HIVP chops proteins packaged in the virion and allows for their 
organization into the viral capsid leading to a mature, infectious virion. Protease 
inhibitors block this process and make these new virions forever immature and unable to 
infect new cells [71]. There are specific guidelines from the FDA for the correct and 
effective combination of these drugs to treat infected individuals. Research continues in 
this field to develop more drugs that may interact less with the host biology and less with 
other drugs allowing for more effective and comprehensive treatment. Without continued 
administration of HAART medication, HIV can restart viral replication and poses a risk 
to develop AIDS [8]. 
II.4 Mast Cell Biology 
In order to fully eradicate HIV from an infected individual, latent reservoirs need 
to be identified. One focus of research today is identifying latent reservoirs present in the 
body and many have been identified [5,9,39-43].  Because of their similarity to T-cells 
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and their ubiquitousness in the body, mast cells have been studied for their susceptibility 
to HIV infection. Mast cells are important immune effector cells that are most often 
characterized for their role in allergic response [72-74]. Hematopoietic progenitor cells 
called myeloid progenitors differentiate into immature mast cells [72-76]. These 
immature mast cells migrate to fibroblast-rich regions in tissue where they then undergo 
limited replication producing daughter mast cells that are fully differentiated [72]. 
Depending on the eventual resting place that the immature cells find, mast cells can 
differentiate into one of two phenotypes in humans. These separate phenotypes are 
identified by their neutral protease composition: either having tryptase, chymase, 
carboxypeptidase A3, and cathepsin G-like enzyme or only tryptase (designated MCTC or 
MCT respectively) [77]. MCTC generally are localized to connective tissue but also have 
populations in some mucosal regions. MCT are more localized to mucosal regions and are 
generally not seen in connective tissue [72]. 
II.5 Mast Cell Activation and Degranulation 
Mast cells are granulocytes having pre-stored inflammatory compounds that are 
rapidly released after introduction to activators [78]. FcεRI is a high-affinity 
immunoglobulin E (IgE) receptor that is typically involved in the allergic response and is 
present on mast cell membrane surfaces [79]. IgE is produced by B-cells as a part of the 
immune system response to allergens [80,81]. FcεRI binds to the heavy chain on the Fc 
region of IgE. IgE molecules are antibodies that are integral parts of the adaptive immune 
system and typically cover the surface of mast cells having bound to FcεRI. When the 
Fab regions of IgE bind to an antigen and the Fc regions bind to FcεRI receptors, a cross-
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linking event occurs that causes a downstream pathway to activate leading to mast cell 
degranulation [82-84]. The first event in this downstream pathway can be the cross-
linking of two or more FcεRI receptors. Following a complex downstream activation, 
mast cells will release their granules filled with various bioactive compounds. Alternative 
methods for activation can circumvent the FcεRI receptor. Toll-like receptors (TLR) are 
pattern recognizing receptors that can recognize various bacterial compounds that are 
structurally conserved [85]. Upon activation, TLR begin a downstream pathway that 
activates mitogen-activated protein kinase (MAPK) leading to degranulation [85]. 
Another method for activating mast cells is by causing release of calcium stores and 
translocating calcium from outside of the cell to the interior [86]. This method can 
circumvent both TLR and FcεRI receptors by interacting with the downstream 
components of the activation pathway like Protein Kinase C (PKC).  
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Figure 2.1 The Binding of an Antigen to the FcεRI-IgE Complex 
 
Mast cells are known to have altered gene expression in the hours following either 
their sensitization or their activation [87,88]. As its terminology suggests, sensitizing a 
mast cell primes the cell to release granules, but little to no granules are actually released 
[89]. After following the activation pathway and releasing granules, mast cells undergo 
many gene upregulations and downregulations. These upregulations help the mast cell to 
continue to help in the immune response even after releasing granules that can recruit 
other immune cells to the site of the antigen [87].  
II.6 Mast Cell Sources 
There are a few ways to procure mast cells. Firstly, there are immortalized mast 
cell lines that have been isolated. HMC-1 was derived from a patient with mast cell 
leukemia [90]. It is noted as being similar to normal mast cells but lacks surface FcεRI 
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receptors which are vital for degranulation. LAD2 cells have minor differences in their 
FcεRI receptors and can effectively degranulate, but there are major differences 
discovered in both LAD2 tryptase and chymase [90]. In an effort to circumvent these 
differences, methods have been developed to procure primary and primary-derived mast 
cells from human donors and have been described previously [91-93]. Mast cells can be 
procured from various tissues including skin, umbilical cords, lung, and most recently fat 
tissue, each with subtle changes in protocol from procurement. Skin mast cells are 
investigated in this dissertation for their susceptibility to HIV infection following 
activation and degranulation. Briefly, their isolation involves the mechanical separation 
of tissue coupled with enzymatic digestion of tissue and followed by separation 
techniques. Culture of mast cells is accomplished generally by the addition of specialized 
X-Vivo media supplemented with human stem-cell factor to encourage multiplication. 
II.7 Fullerenes 
Fullerenes have been the subject of investigations in biological applications for 
some time. Their use has been included in demonstrations as antioxidants, drug delivery 
vehicles, therapeutics, diagnostic tools, photo-sensitizers, anti-cancer, and as anti-viral 
treatments [94-106]. The native fullerene is not soluble in water and can be derivatized 
for various functional moieties. This ability to bind moieties to the carbon cage can lead 
to various functionalizations. Fullerenes are unique because of their electrochemical 
characteristics and are capable of undergoing various chemical reactions that can alter 
their reactivity, permeability, solubility, or targeting ability. The fullerene derivative (FD) 
has new physical and chemical properties. 
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Many fullerenes are known to be effective antioxidants. They act as “free radical 
sponges,” and can readily accept electrons from reactive oxygen species (ROS) found 
commonly in cellular systems [107]. ROS many times have unpaired electrons that 
readily react with native molecules inside the cell causing oxidative stress. This oxidative 
stress can lead to problems including cellular malfunction or dysfunction and can lead to 
cell death. Accordingly, oxidative stress has been implicated as a primary method for 
aging [108]. The cell has systems in place to either use these free radicals as signaling 
molecules or as cellular defense mechanisms, but more often uses proteins like 
Superoxide Dismutase (SOD) to convert them into either harmless compounds or into 
more manageable compounds [109]. There are several known ROS known to cause cell 
damage. They include hydroxyl radicals (HO•), superoxide anions (O2
-
), and 
peroxynitrites (ONOO
-
). 
Because of the commonality of these damaging compounds, much research has 
pointed to the benefits of antioxidants against more systemic diseases. It has become 
widely accepted that antioxidants provide benefits to general health. Following the 
discovery of fullerene’s ability to counteract ROS, various FD have been developed and 
used in experiments with promising results. N. Gharbi et al showed that micro-dispersed 
C60 fullerenes had no adverse effects on liver toxicity and worked to stem the effects of 
an oxidant challenge (CCl4) in rats [94]. This group went on to show that lifespans of rats 
is almost doubled with the administration of oral olive oil dosed with C60 fullerene 
[110]. Another study showed their comparative effectiveness of a FD to the native SOD-1 
enzyme and found it to mimic its activity [111]. The researchers did this by dosing SOD2 
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(-/-) mice with a Tris-malonic acid C60 fullerene (C3) and increased their lifespan by 
300%. Another study by some of these authors showed that FD had neuroprotective 
capabilities in neuronal cell cultures [112]. Fullerenes and their derivatives show 
potential as antioxidants in treatments for diseases caused by ROS. 
Many researchers today are investigating alternative methods for drug therapy 
[96]. Fullerenes have been investigated as drug delivery vehicles because of their 
potential for derivation and their small size. Water soluble FD can easily cross cell 
membranes or, depending on the functionalization of the carbon cage, can bind 
specifically to a target biomolecules [113]. Beyond water solubility and biomolecular 
targeting, fullerenes can also be functionalized to become carriers of drugs or genes. 
Some examples of this possible use are their use as allergic response mediation, their 
ability to suppress the asthma reaction, their ability to dampen inflammation caused by 
arthritis, their potential as a therapy for multiple sclerosis, and their ability to inhibit viral 
process, including in HIV infections [26,98-102,104,114]. 
Fullerenes may also be shown to be effective diagnostic tools. Researchers at 
Virginia Tech were able to successfully produce fullerenes that encapsulated 3 
gadolinium atoms bound by a central nitrogen atom contained inside the carbon cage. 
These “Trimetaspheres” (TMS) were demonstrated to be strong MRI contrast agents 
[98,115]. Researchers hope to overcome limitations caused by more conventional MRI 
contrast agents like Magnevist
TM
 that can release its toxic, chelated gadolinium ion upon 
host degradation of the bound carrier. TMSs may also outperform Magnevist
TM
 as far as 
body retention over time and body targeting ability because of the functionalization of the 
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carbon cage. This leaves a possibility for fullerenes to be used as both a therapeutic and 
diagnostic tool simultaneously. By selectively functionalizing moieties to the surface of a 
fullerene cage, while all the while leaving the gadolinium triad unchanged within the 
cage, a FD can be made to perform targeting, therapy, and diagnostics. The term 
“theranostic” has been used for this functionality and very well could be the future of 
medical practices [100]. Nanoparticles of various compositions are being investigated as 
diagnostic tools already and some fullerene platforms are attractive targets for the 
theranostic technology. One particular investigation by Dellinger et al used 
functionalized TMSs in liposomes to target atherosclerotic plaque lesions in ApoE knock 
out mice [98]. These TMSs were further functionalized with CD36 ligands which were 
instrumental in the cellular uptake of the fullerenes into the cells in the atherosclerotic 
plaque. Mice were then imaged using MRI showing the gadolinium present in the 
atherosclerotic plaques. This technology can be adapted to be used in various other 
treatments by changing the functionalization of the TMS.  
There are also variations of fullerenes. The classic and most well-known fullerene 
is the C60 “buckyball”, comprising of 60 carbons arranged in a “soccer ball” 
configuration. Other fullerene configurations include C20, C26, C70, C72, C76, C80, 
C84, and C100, each being empty carbon cages with varying amounts of 5 and 6 
membered rings. As mentioned above, fullerenes have been designed that carry a triad of 
metal ions, usually gadolinium, and can be used as an effective MRI contrast agent. 
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II.8 Toxicity of Fullerenes 
The basis for determining toxicity and consequently determining the possibility 
for use in humans is regulated by the FDA. Any new chemical compound or treatment is 
required to be evaluated separately, despite the similarity to other chemicals in the same 
class. Beyond the purely chemical variations between fullerene derivatives, there are 
variations between different fullerenes. Differences in isomeric configurations and 
differences in cage size allow for even more variations making the toxicologist’s job even 
more intricate. According to FDA guidelines, each isomer and each cage can have 
different interactions with biological molecules and should be investigated accordingly. 
One of the common and primary functionalizations of fullerenes is water 
solubilization, but not all water soluble fullerenes act similarly. Investigating each 
fullerene separately should be a priority of each toxicity study. It is clearly evident that 
certain FDs behave differently than others in biological systems and that fundamental 
understanding helps to ensure limited negative effects caused by small changes from one 
to another fullerene derivative.  
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Figure 2.2 Representative C60 Fullerene Derivatives. 
 
Because of the wellspring of opportunity presented in fullerenes and their 
derivatives, much attention has been given to their potential toxicity. Many of these 
studies have conflicted with each other and have led to a debate over the nature of their 
toxicity. The most notable and notorious study concerning the toxicity of fullerenes was 
performed by Oberdorster [116]. In this study, fullerenes were given to juvenile 
largemouth bass following an incomplete characterization and lacked a proper control 
which led to conclusions that could not determine if the toxicity was due to the size of the 
aggregates, the composition or chemical nature of the aggregates, or the tetrahydrofuran 
contamination. Unfortunately, media outlets discovered this study and publicized its 
unfounded conclusions, which led to an atmosphere of wariness of the fullerene’s future 
in the field of biology or medicine. Because of backlash over the failures of the original 
study, researchers followed with a more expansive examination that concluded that the 
impurities in the sample were the cause for any toxicity seen in the first study [117]. 
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Other investigations into the subject of fullerene toxicity have demonstrated increases in 
the lifespan of mice [118] and rats [110]. Intending to explore the over dosing of 
fullerenes to organisms, other researchers treated mice with excessive dosages but still 
showed no overt toxicity [94,119]. More recently fullerenes suspended in olive oil were 
fed to rats and led to a 90% longer lifespan compared to control mice [110]. 
Conflicts, especially between highly publicized studies, make it difficult for 
researchers to effectively develop novel treatments based on a fullerene platform because 
of the perceived potential harm that they could cause. It is therefore necessary to ensure 
that further investigations into the toxicity of fullerenes (and any nanomaterial for that 
matter) are carefully constructed to account for the many variables that could contribute 
to the perceived toxicity. 
II.9 Mast Cells and HIV 
Mast cells are often found in mucosa and other host-environment interfaces. 
Because of their positioning and because they are important immune effector cells that 
help in pathogen defense, MC’s role in HIV infection is unclear [11]. The genital 
mucosae of HIV infected women showed increased MC density. Other examples of noted 
mast cell population increases were found in men with AIDS associated diarrhea [12]. 
These increased MC populations suggest that MCs are involved in the body’s response to 
the infection. 
II.10 Mast Cells’ Susceptibility to HIV Infection 
Previous investigations into the hypothesis that mast cells are susceptible to HIV 
infection have shown varying results. It has been shown that progenitor mast cells are 
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susceptible to infection by HIV, suggesting that the low levels of CD4 that were detected 
on these cells were enough to establish an infection [9,10,13-16]. Importantly, these 
progenitor mast cells appear to lose their susceptibility to HIV after a certain point in 
their ontogeny. These infected progenitor cells then produce daughter cells that 
terminally differentiated into mast cells that then reside in tissue and may establish a 
latent reservoir [13,14]. This evidence that mast cell progenitors and other hematopoietic 
progenitors can be infected allows for possible HIV reservoirs even after maturation.  
Other primary mast cells have been examined. Fetal liver blood-derived mast cells 
were examined for their susceptibility to X4 tropic HIV and were productively infected 
[17]. It was unclear in this study if the primary cells in the experiments were progenitors 
or terminally differentiated. Another study demonstrated that p24 does not co-localize to 
skin mast cells obtained from various tissue sites [18]. Multiple tissue sites were 
examined including the lymph nodes, cervix, GI tract, and parotid glands but no mast 
cells were found to be actively producing p24, a HIV specific protein by 
immunohistochemistry. 
Most recently, mast cells taken from gastrointestinal mucosa of healthy patients 
undergoing surgery and were introduced to HIV. The researchers found that mast cells 
are able to present virus to other CD4+ cells. This is facilitated by some HIV-1 
attachment factor; some of these factors include DC-SIGN, HSPG, and α4 β7 integrin 
[19]. This means that mast cells can support HIV infections by capturing HIV and 
presenting it to susceptible cells. The researchers also investigated the susceptibility of 
these mast cells to infection and found that they could be infected. 
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Further studies have examined the immortalized mast cell line, HMC-1, and 
found that infection was possible [17,20]. The cell line was infected in both cases. It 
should be noted that HMC-1 is a poor substitute for primary human mast cells because it 
lacks the expression of FcεRI [120,121]. 
To our knowledge, primary, skin, human mast cells have not been studied for 
their susceptibility to HIV in vitro. Further, no studies have examined the effect of 
activators on primary mast cells and their potentially altered susceptibility to HIV as a 
result of activation. Mast cells are one of the first immune cells that HIV encounters in 
vivo and may become a target for HIV under certain inflammatory conditions. We 
hypothesized that terminally differentiated human mast cells (possibly through IgE-
dependent and/or independent activation) can be infected by HIV and represent a new 
viral reservoir. We therefore tested this hypothesis and the results are discussed in later 
portions of this dissertation. By identifying various cellular reservoirs of HIV, a greater 
understanding of the life cycle of the virus is revealed and this understanding may present 
new opportunities for medical professionals to more efficiently treat individuals infected 
with the virus. 
II.11 Fullerenes and HIV 
There have been many studies investigating the possibility of use of fullerene 
derivatives as HIV inhibitors. The first study following this hypothesis was done by 
Friedman et al who identified the similarity in size and hydrophobicity of the carbon cage 
of fullerenes and the viral enzyme protease (HIVP) [25]. They suggested that FDs may 
act as powerful HIVP inhibitors by acting as antagonists to the HIVP active site. They 
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identified two compounds using molecular modeling that seem to affect the enzyme’s 
ability to work effectively and tested both computationally and experimentally. 
Researchers from this original work then continued their work and generated 6 new FD 
as possible HIVP inhibitors [26]. The next study investigated a highly water-soluble 
dendro[60]fullerene originally synthesized by Brettreich and Hirsch [122]. This 
investigation showed this fullerene to be highly effective at inhibiting HIV [27]. More 
studies have looked at the inhibitory effects of fullerene derivatives on HIVP because of 
the fullerene derivatives’ interaction with the active site of HIVP [28,123-130]. From all 
of these, many different FDs have been identified as HIVP inhibitors. Most recently, 
fullerene derivatives that used the carbon cage as the platform for an amino acid inhibitor 
were shown to be effective HIVP inhibitors [130]. Modeling studies performed in this 
study indicated that the amino acid chain was more likely to interact with the active site 
of the protease and overestimated their inhibitory effect. Subsequent experiments utilized 
a FRET-based assay that revealed strong inhibitory effects on the protease. 
However, HIVP may not be the only target for fullerene derivatives. Some 
fullerene derivatives may target other essential components of the viral reproduction 
cycle. Fullerenes have been shown to interact with NF-κB functionality [131], G-protein 
coupled receptors (GPCR) [132], amyloids [133], coagulation [134], and, most 
interestingly for this discussion, HIV Reverse Transcriptase [135]. Amyloids are 
important transmission vehicles for HIV [136]. HIV uses amyloids as attachment and 
fusion facilitators and fullerenes can be used as anti-amyloid compounds [133]. The 
relationship between HIV and coagulation is still unclear. It has been shown that 
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thrombocytopenia is a common symptom of infected individuals [137] and the addition 
of certain fullerene derivatives may help with that condition. HIV hijacks the NF-κB 
transcription factor to produce transcripts of viral genes initially and the interruption of 
this process can decrease virion production [38,138]. CCR5 and CXCR4 are GPCRs that 
are used during the attachment and fusion steps of HIV infection. It has been shown that 
certain fullerene derivatives can interact with certain GPCRs and this interaction may 
also be produced with either CCR5 or CXCR4 [132]. This may lead to the fullerene 
acting as an attachment or fusion inhibitor disallowing infection. 
 
 
Figure 2.3 Fullerene Derivative Docked into the Active Site of HIV Protease. 
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Though most studies involving HIV and fullerenes have focused on the HIVP-
fullerene interaction and the resulting proliferation inhibition, Mashino et al investigated 
the role of eight different FDs as HIV Reverse transcriptase inhibitors [135]. Each 
described had an inhibitory effect on reverse transcriptase’s activity. Using a radiometric 
method, IC50 values were obtained and the fullerene derivatives scored moderately well 
compared to a Nevirapine control. Nevirapine is a commonly used non-nucleoside 
reverse transcriptase inhibitor in HAART. Interestingly, these same fullerene derivatives 
were examined as hepatitis C virus RNA polymerase as well in this study. 
Comparatively, the fullerene derivatives were better inhibitors of the HCV polymerase 
than the HIVP. 
Fullerene derivatives are an exciting new platform for the design of novel anti-
HIV compounds. The primary mechanism for HIV inhibition seems to be through HIVP, 
but there are other relevant mechanisms through which a fullerene derivative can 
interrupt or retard the processes of HIV. Alternatively, by binding a previously known 
inhibitor to the carbon cage, fullerene derivatives may be able to serve as effective 
carriers of inhibitory compounds and their use can be expanded beyond HIVP or reverse 
transcriptase inhibition. Various fullerene derivatives previously not investigated for their 
role in HIV inhibitions are investigated in this dissertation as potential anti-HIV 
compounds and their likelihood for acting as protease inhibitors is explored through 
computational docking studies.
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CHAPTER III  
PRIMARY HUMAN SKIN-DERIVED MAST CELLS 
1 ARE NOT A RESERVOIR FOR HIV 
 
III.1 Introduction 
Human immunodeficiency virus (HIV) is the virus that causes acquired immune 
deficiency syndrome (AIDS). While Highly Active Anti-Retroviral Treatment (HAART) 
medications have been efficacious in suppressing viral replication, once it is 
discontinued, virus emerges from cellular reservoirs [39,43]. However, it is not clear 
what cell types the virus uses as latent cellular reservoirs. Mast cells are ubiquitously 
expressed immune effector cells residing in tissue and mast cell progenitors can be 
infected with HIV, which can lead to a latent reservoir in tissue in humans [9,10,13,17]. 
Other studies using mast cell-like cell lines or mast cells derived from progenitor cells in 
the blood can be infected [17]. Most recently, mast cells from gastrointestinal mucosa 
were shown to be susceptible to HIV infection [19] while other studies found no evidence 
of active replication in mast cells [18]. Given that mast cells are one of the first immune 
cells that HIV encounters in vivo, we hypothesized that primary human mast cells would 
be susceptible to infection by HIV. We also recognized that mast cells have altered gene 
expression following a degranulation event and the method of that degranulation may 
affect the altered gene expression as described previously [87,88]. We therefore further 
hypothesized that mast cells could be infected by HIV following FcεRI or non-FcεRI 
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receptor dependent challenge with various secretagogues and serve as a latent reservoir 
for HIV. 
III.2 Methods 
III.2.1 Mast cell culture and degranulation 
 To test this hypothesis human, skin-derived, mast cells, which proliferate from a 
yet to be defined stem cell population, were challenged with live HIV [139]. Mast cells 
were cultured in X-VIVO media (Lonza Inc., Allendale, NJ) supplemented with human 
Stem Cell Factor (SCF) for 12 to 20 weeks. At this point, cells were collected, counted, 
and examined for viability with Trypan-Blue exclusion. Mast cells, at <90% viability, 
were plated in duplicate in a 24 well plate (5 x 10
5
 cells/well) and were activated with 
FcεRI-dependent (anti-FcεRI-alpha receptor antibody 3B4) or non-FcεRI-dependent 
stimuli Calcium Ionophore (A23187, 0.1 μg/mL) or Lipopolysaccharide (LPS; 1.5 μg/ml) 
overnight. 
III.2.2 Viral introduction to mast cells 
The following day, media was removed and replaced by fresh X-VIVO 
supplemented with SCF, and then live HIVLAI (NIH AIDS Reagent Program, 
Germantown, MD) was added to each well at a multiplicity of infection between 0.1 and 
0.5 and incubated for 5 days. After 5 days cells were washed three times and left to 
incubate overnight in new, virus-free media to allow for any non-internalized virus to 
either infect or be released from non-specific adhesion to cellular plasma membranes. 
After a final wash, cells were suspended in water for subsequent PCR preparation.  
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III.2.3 Viral DNA detection by PCR  
Mast cell cultures were suspended in water and sonicated in heated water baths 
(70
o
C) to lyse cells and disrupt membranes as well as kill any remaining virus present for 
ease of handling. A phenol extraction was then used to isolate DNA and purity was 
assessed by a NanoDrop 2000 Spectrophotometer. For detection of viral DNA by PCR, 
the primers used were: Alu FWD: 5’ – GCC TCA ATA AAG CTT GCC TTG A – 3’ and 
gag REV: 5’ – CAT CTC TCT CCT TCT AGC CTC – 3‘ (Integrated DNA Technologies 
Coraville, Iowa). 
 
 
Figure 3.1 HIV Does Not Infect Human Skin Mast Cells 
 
III.3 Results 
III.3.1 Human, skin-derived mast cells are not susceptible to HIV 
As shown in Figure 1, mast cells did not become infected with HIV under resting 
or stimulated conditions as assessed by PCR of the HIV-specific marker DNA (Figure 1). 
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Previous to introduction of HIV to mast cells, mast cells were activated with 3B4, 
Calcium Ionophore A23187, or LPS and the percent release compared to total and 
spontaneous release controls. As a control, a t-lymphoblast cell line with a green 
fluorescent reporter gene called CEM-gfp were actively infected as assessed by p24 
expression and gfp upregulation (Figure 1B,C). As expected no viral proteins were 
detected in the mast cell lysates using Western blotting (not shown). 
 III.4 Conclusions 
Though other mast cell sources have produced mast cells that are susceptible to 
HIV infection, this study suggests HIV does not infect human skin mast cells or the 
progenitors that give rise to them and therefore do not serve as a reservoir for HIV. There 
are some possible explanations for this. There are at least two different phenotypes of 
mast cells in the body and they are distinguished by the neutral protease composition 
found in their granules and are designated with the notation MCT and MCTC (representing 
Tryptase (T) and Chymase (C)) [72,74,140,141]. Skin mast cells are generally considered 
as being comprised of primarily MCTC and their composition of these tissues can be a 
contributing factor to the susceptibility of these skin-derived mast cells. Another 
possibility is that contrary to previous investigations, our cell populations, which do 
undergo some limited replication, are devoid of the CD4+ progenitor mast cell 
populations. This hypothesis could be examined by a more complete characterization of 
this mast cell population that would separate the fully differentiated mast cells and the 
progenitors and examine the presence of CD4 on both populations. This characterization 
would be greatly improved with multiple samplings throughout the culture of the mast 
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cells from tissue as it could show if and when the CD4 surface receptor as well as any 
other important or interesting biomolecules.
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CHAPTER IV 
FULLERENE DERIVATIVES SHOW POTENTIAL ANTI-HIV ACTIVITY 
 
IV.1 Introduction 
IV.1.1 HIV 
Human immunodeficiency virus (HIV) causes acquired immune deficiency 
syndrome (AIDS). Current treatments for HIV+ individuals include Highly Active Anti-
Retroviral Therapy (HAART) designed to inhibit retroviral proliferation and survival and 
is commonly used in the treatment of retroviruses [142]. This therapy is responsible for 
increased longevity for HIV+ individuals by decreasing the probability of progression to 
AIDS. This treatment, however, is not able to fully eradicate the virus from an infected 
individual as HIV establishes long term latent reservoirs in cells that harbor the virus 
indefinitely and protect it from immunogenicity. An individual who is HIV+ and 
suspends their HAART treatments quickly progresses to AIDS because of these latent 
reservoirs. One of the focuses of HIV research today is the discovery of new treatments 
that inhibit viral processes. Researchers have identified many fullerene derivatives (FD) 
that may serve as a new platform for new anti-viral compounds and this study adds to that 
body of knowledge. 
IV.1.2 Fullerene derivatives viral inhibition 
Fullerenes are an allotrope of carbon that features a closed cage of carbon that is 
hollow inside and this class of compounds has been used extensively for a variety of 
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biological applications [112,132,143]. Several studies have looked at the modeled 
dynamics of the interaction between various functionalized fullerenes and the viral 
protein protease or used fullerene derivatives (FDs) as viral inhibitors in vitro [25-
28,123-130,144,145]. HIV protease is an especially desirable therapeutic target as it is 
responsible for cleaving immature viral proteins in the life cycle of HIV [146]. Without 
protease, newly budded HIV virions do not mature and are less likely to be infectious 
[22]. Because these FD have some sort of a competitive mode of action by binding to the 
active site, HIV protease generally is the studied protein in docking simulations. 
Fullerenes were originally identified as promising protease antagonists because of the 
hydrophobicity of the active site of protease [25]. Thus, some functionalized fullerenes 
that are water soluble but still have large portions of their hydrophobic cages accessible 
can fit directly into the active site of the protease effectively acting as an antagonist. 
Some fullerenes have been tested in this capacity and were shown to be effective at 
limiting the virus’s proliferation [25,27,126,127,130,135]. 
Our lab has been interested in fullerene interaction with biological processes and 
we have previously used fullerenes in other studies as both therapeutics and diagnostics 
[98,99,101,102,114,147]. We wanted to see if these fullerenes that had many beneficial 
effects on other systems could be employed in an antiviral capacity following the 
precedent set by other researchers using FDs as anti-retroviral compounds. We therefore 
set to test a panel of seven FDs as potential HIV inhibitors with the hypothesis that, 
similarly to other fullerene-HIV studies, these FDs would also be effective at inhibiting 
HIV. 
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IV.2 Methods 
IV.2.1 Modeling methods 
A panel of FDs (Figure 1) were modeled and minimized in Sybyl modeling 
package using the Tripos molecular mechanic force field. Another fullerene (named 
Trans-3)(structure not shown) was also modeled and examined as a positive control in 
modeling experiments because it had been described previously as being effective at 
inhibiting HIV [127]. Another positive control used in modeling experiments was 
Ritnoavir, a commonly used drug in HAART medication for the inhibition of HIV 
protease [148].  Since the HIV protease structure has not been determined experimentally 
with a fullerene bound in the active site, the initial structure for HIV protease used in 
these modeling experiments was derived from a databased structure complexed with a 
Fluoro-substituted diol based C2-symmetric inhibitor (pdb code 1W5X). Water 
molecules and the bound inhibitor were removed and analyzed using the Surflex Docking 
Module within the Sybyl modeling package. Residues present in the protease were 
amended to be neutrally charged based on previous investigations that suggested that 
there appears to be no significant differences in docking of FD into HIV protease 
between charged and neutral protease residues [128]. FDs were then docked into HIV 
protease using the Surflex Docking module within the Sybyl modeling package for 
preliminary indications of FD ligand docking. Hydrogens and heavy atoms were allowed 
to move and minimized before and after ligand fitting. Results were derived from Total 
Score values produced from the docking program. 
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IV.2.2 In Vitro methods 
IV.2.2.1 CEM-gfp cell line 
In vitro experiments were performed in CEM-gfp cells. CEM-gfp cells are an 
immortalized T-cell line that has been stably transfected with a gene that codes for green 
fluorescent protein with a promotor region of the gene that is bound by the HIV 
transcription factor tat (trans-activator of transcription). Therefore, gpf is produced in 
response to the presence of viral protein tat, indicating a particular cell is infected by 
HIV. 
IV.2.2.2 Experimental design 
CEM-gfp cells were plated at 100,000 cells per well in a 24-well plate. FDs were 
then added and cells were allowed to incubate overnight. Seven different fullerenes were 
surveyed and are shown in Figure 1. HIV populations were expanded in separate CEM-
gfp cultures from an original HIVLAI stock (NIH AIDS Reagent Program, Germantown, 
MD). Expanded viral supernatant was then added the next day equally in appropriate 
wells at a multiplicity of infection between 0.1 and 0.5. Measurements of gfp 
fluorescence were taken each day using a BioTek SynergyMx Microplate Photometer. 
Cells were incubated in the presence of FDs and virus for at least five days. Media was 
not changed during the duration of the test to allow HIV population growth to be 
unhindered. Mean fluorescence intensity values were used to determine the proliferation 
of the virus in comparison to a control population that received no FDs. For the survey, 
the concentration of each FD was 5μg/mL. 
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Figure 4.1 Graphical Representations of the FDs Used in this Study. 
IV.2.2.3 Fullerene dose response experiments
Following results of the initial survey of seven fullerenes, dose response 
experiments were performed following a similar protocol used for the initial survey. Cells 
were plated at 100,000 cells per well in 24 well plates. Varying concentrations (0.01, 0.1, 
1, 5, and 20 μg/mL) of three FDs that appeared to work well in the original survey were 
used. Readings of gfp fluorescence were taken each day and compared to negative and 
positive samples present in each plate. Dose response experiments using the three 
selected FD were repeated three times in duplicate. 
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IV.3 Results
IV.3.1 Modeling results suggest complementarianism 
To test the hypothesis that any of these FD had any effect on the activity of HIV 
Protease, FD (Figure 1) were submitted as ligands to the Surflex docking module in the 
Sybyl modeling package. The module produced Total Scores that ranked ligands as 
candidates for fitting into the active site. Total score values are listed in Table 1. Scores 
are ranked by their positive magnitude meaning that the highest scoring ligands were 
those that received larger positive values and those that scored low are those close to or 
below zero. Additionally, these score values suggest the relative likelihood that an 
interaction was possible in that conformation between the ligand and the viral protease. 
Table 1 also lists the various residues which participated in hydrogen bonding with the 
ligand docked in the most highly scored ligand orientation. Interestingly, there appeared 
to be no correlation between the multiplicity of hydrogen bonding instances and Total 
Scores. Certain FDs were scored very highly in possible interactions with HIV protease 
including C3, NEPO, ALM, and C60OH. For both ALM and TTA, the highest scoring 
conformation did not include the integration of the fullerene cage within the active site of 
the viral protease. Instead, the moieties decorating the surface of the fullerene cage were 
occupied the active site more exclusively. 
IV.3.2 In Vitro experiments show some inhibitory effect of FD 
Mean Fluorescence Intensity was measured over the course of five days. The raw 
values were then normalized and compared to a positive control that had no FDs but did 
receive virus. This Percent Inhibition of gfp is displayed in Figure 3. After an initial 
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survey of the seven FDs, three FDs (NEPO, TTA, and C3) with stronger suppressive 
effects at the surveyed concentration of 5 μg/mL were selected for dose response 
experiments. Dose response experiments used concentrations of the three FD of 0.01, 0.1, 
1, 5, and 20 μg/mL. Raw values were compared to positive controls that were introduced 
to virus but not FDs to give a percent inhibition compared to control. Values were then 
averaged together from three dose response experiments and are presented in Figure 4. 
Dose response experiments were repeated three times in duplicate. 
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Table 4.1. FDs and Their Total Scores Assigned to Them by the Docking Module. Certain 
residues are also listed that had hydrogen bonding with the ligand. Positive controls of 
Ritonavir and a FD that had been shown previously to be a suppressor of HIV Protease 
are also present [128]. Ligands marked with a (*) had their strongest interaction with 
HIV protease only with the fullerene cage outside of the active site. These ligands 
generally interacted with the active site with their bound moieties. Residues marked with 
a (**) participated in multiple instances of hydrogen bonding; multiple atoms of the 
residue was able to participate in hydrogen bonding. 
Ligand (FD) Total Scores Protease Residues involved in H-Bonding 
C3 4.8628 ASP30, ASP25, ASP29, LYS45, ARG8 
NEPO 12.6611 ASP25, GLY27, GLY48, ILE50, THR80 
C60OH 5.2109 
ARG8, ASP29, ILE47, GLY48, GLY49, ILE50, 
THR80, VAL82 
ALM* 10.5172 ARG8, ILE50 
C70OH 0.2040 
ASP25, GLY27, ALA28, ASP29, ILE47, 
GLY48**, ILE50 
TGA -2.0682 ARG8, ASP29, ASP30, LYS45, GLY48 
TTA* -1.9429 ARG8, ASP29, ASP30 
Ritonavir 1.9402 ASP25** 
Trans-3 4.7939 none 
36 
Figure 4.2 Representative Picture of a FD (C3) Docked Into HIV Protease Active Site. 
37 
Figure 4.3 Percent Inhibition of gfp Fluorescence in HIV+ CEM-gfp Compared to 
Positive Control. 
38 
Figure 4.4 Average Percentage of MFI Inhibition. 
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IV.4 Discussion 
Fullerenes and their derivatives represent a promising platform for the design of 
targeted therapies because of their predisposition to chemical attachment. Chemical 
moieties decorating the surface of fullerenes allow for the compound to be customized to 
various applications. This study explored the possibility of various C60 and C70 FDs to 
be used as HIV inhibitors. Previous investigations have explored FD interactions with 
both HIV protease [25-28,124,126-128,130] and HIV reverse transcriptase [135] and this 
study aims to add to that knowledge. 
While FDs C3, NEPO, C60OH, and ALM scored well in the docking simulations, 
not all of these were effective in vitro. The reasoning for this is unclear, but there likely 
are multiple interactions in which these FDs are involved. Further studies are required to 
more concretely elucidate the possible interactions these FDs have in vitro. C3 and NEPO 
were originally effective in the survey and had some apparent interaction at other 
concentrations as demonstrated with the dose response experiments. This may mean that 
these two FDs have some interaction with protease, but the data is unexpected. Generally, 
dose response assays show a characteristic increase in efficacy over the dosage range 
until a threshold concentration where toxicity is apparent is reached. Instead, the dose 
response results suggest that these FDs are likely involved in other interactions. 
Alternatively, like other FDs that appeared to have no effect, these FDs are not 
interacting with the viral protease at all, but are instead interacting with other 
mechanisms that result in inhibition. To examine these possibilities, further experiments 
are needed. Examinations of the FD’s interaction with various viral proteins through 
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reporter kits would be invaluable for the determination of the method of action. 
Alternatively, reporter substrates generated from transfected genes for the possible 
mechanisms of action could be used as a screening tool for the presence of inhibition at 
various steps of the viral infection pathway. For example, a gene that codes for both the 
natural substrate for HIVP as well as for a reporter that fluoresces after the natural 
substrate has been cleaved would help identify interactions of the protease with a FD. 
Importantly, this example would only be able suggest an interaction and would not show 
exclusivity of the interaction and would not show other characteristics of the interaction 
like the length of the interaction. 
Interestingly, though TTA did not score well in simulations, it was effective at 
limiting viral proliferation in vitro. There are some possible explanations for this result. 
While HIVP is the most common target for HIV inhibition using FDs, it is not the only 
one that has been reported [135]. TTA very likely is having some effect on some other 
viral process and stopping the virus from replicating. Similar studies suggested earlier 
could also be translated to determine TTA’s mechanism of action by including analytical 
tests for other viral specific proteins like reverse transcriptase or integrase. Alternatively, 
TTA may be intimately involved with some host mechanism that HIV requires for 
replication. TTA may have interactions with the surface chemistry necessary for HIV 
internalization and disable the virus from entering the cell entirely. To test for these 
interactions, reporter viral strains that have been engineered to report upon internalization 
could be employed. Fullerenes have also been shown to interact with various cellular 
processes; this includes the NF- κB pathway [131]. Because the activation of NF- κB is 
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regulated by a large downstream pathway consisting of many proteins and protein 
complexes, the most comprehensive test to examine all interactions would be a 
phosphoproteomic study of the NF- κB pathway. This examination would allow us to 
determine the phosphorylation state of each of the proteins in the pathway and look for 
any blocking caused by a FD dose. While we could examine individual bonding instances 
with FDs and certain parts of the pathway, this proposed examination would be able to 
screen multiple FD treatments as well as screen multiple possible instances of 
interactions.  
In the instance of ALM, this FD is known to have interactions with other 
biological molecules including lipid bilayers. Accordingly, ALM may be present only in 
areas of the cell that are not involved with viral processes. As such, even though ALM 
scored highly on the docking simulations, it likely was not effective as a protease 
inhibitor (or as any other inhibitor for that matter) because it was sequestered away in 
membranes. In HIV protease interaction experiments examining other FDs, ALM should 
still be included. ALM itself may not have any in vitro effect, but its moieties could still 
be of use as an inhibitor, just bound to another platform. This study is helpful as 
screening method development for detecting inhibition of HIV proliferation, but 
admittedly does only suggest an interaction. Additional computational studies may 
illuminate interactions between FDs and other viral proteins like reverse transcriptase, 
but, like the computational studies performed here, they will only be able to suggest 
interactions. Further experimentation that analyzes specific FD interactions with host and 
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viral proteins is needed to fully determine the mechanisms of action through which these 
(and other) FD disrupt the natural viral processes. 
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1 CHAPTER V  
FUTURE PROSPECTIVES 
 
HIV has been studied extensively. Continued research efforts are likely to focus 
on identifying new latent reservoirs and drug classes intended to further inhibit the 
virus’s pathology. The hope is that at some point a way to fully eradicate the latent 
reservoir will be discovered. However, this solution will likely include some measure of 
either permanently disabling the integrated viral DNA or killing the latently infected cells 
altogether. Some options for the latter have been explored by firstly activating the latently 
infected cell population to produce virus and then targeting the virus expressing cell for 
extermination [6]. There are complications that make this approach difficult and 
researchers are actively exploring other opportunities. 
Another method for the eradication of HIV and the latent reservoir is through 
bone marrow transplantation. To date, one individual has been functionally cured of HIV 
infection. The highly publicized study described the case of Timothy Brown, commonly 
referred to as the “Berlin Patient”, as his medical problems were solved [149]. Briefly, 
Brown was diagnosed with HIV in 1995. He was prescribed anti-retroviral treatment and 
remained on the treatment until 2007 when he was diagnosed with Acute Myeloid 
Leukemia. Brown was living in Germany at the time and his doctors decided to give him 
a stem cell transplant from a donor who expressed a homozygous CCR5 ∆32 mutation 
and, after enduring many complications, recovered from both his leukemia and HIV 
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infection. This mutation is present in a small percentage of the population and it causes 
the CCR5 receptor to no longer have an extracellular region. This then means that the 
virus struggles to infect cells because it cannot perform the secondary binding event with 
CCR5. For the “Berlin Patient,” this transplantation resulted in a newly acquired natural 
resistance to the virus. Brown reports that he has since discontinued his HAART 
medication and remains free of detectable virus to this day. This same method for 
treatment was lauded as a possible blueprint for the eradication of HIV in infected 
individuals and thus is being explored to solve complications caused by the treatment and 
in turn make it more robust. 
The option to more fully eradicate the presence of detectable virus in HIV+ 
individuals has further spurred the creation of more diverse treatment options. Because 
HAART medication only reduces the probability of progression to AIDS and because the 
virus easily mutates to circumvent treatment and immune responses, more robust 
treatment options are necessary for more indefinite control of the virus [150,151]. 
Furthermore, many of the currently available HAART treatments are accompanied by 
unwanted side-effects. These are some of the main reasons that fullerene derivatives and 
other more unconventional drug development strategies have been employed in research 
studies to find replacements and alternatives [130]. This trend will likely continue until a 
reliable, functional cure for HIV is produced. 
There are complications, however, with the development of FD based treatments. 
Though fullerenes and their derivatives are generally regarded as non-toxic and have 
notable beneficial effects [110,112,152-155], the FDA is understandably strict with the 
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composition and predictability of drug interactions [156]. Accordingly, many FD drug 
candidates are expected to be comprised of the C70 fullerene cage over the C60 cage 
because of the increased predictability of moiety binding positions. C70 cages are 
arranged in a more ellipsoidal shape and that ellipsoidal shape prefers binding on the 
opposite ends of the major axis [147,157,158]. This characteristic allows for more 
predictable attachment of surface moieties and is likely to be preferred by the FDA.  
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